DexCom (DXCM) announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. The company said, “Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. Dexcom Flex reflects the company’s commitment to placing people at the centre of the product design process and creates a personalised diabetes guidance experience, rather than offering a one-size-fits-all approach.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $80 from $100 at BofA
- DexCom price target lowered to $82 from $100 at Canaccord
- DexCom price target lowered to $64 from $67 at Barclays
- Morning News Wrap-Up, 5/15/26: Today’s Biggest Stock Market Stories!
- Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports